Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07424378 · ClinicalTrials.gov registry record · Phase 4
Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)
A Phase 4 study, sponsored by University of Colorado, Denver.
- Not yet
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
NCT07424378 is a Phase 4 study that has not yet begun recruiting, run by University of Colorado, Denver. The registered enrollment target is 66 participants.
The verdict
NCT07424378, a Phase 4 study, has not yet begun recruiting, sponsored by University of Colorado, Denver.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
Study Summary
Severe frostbite injury can result in significant lifelong disability and amputation. Various medicines, including intravenous vasodilators (prostaglandins/iloprost, pentoxifylline, buflomedil) along with thrombolytics (alteplase), have been described to counter tissue ischemia after rewarming, with poor quality of evidence. An in-class prostacyclin, epoprostenol, has similar pharmacodynamic properties to iloprost including vasodilation and platelet inhibition and has been used in peripheral tissue ischemia such as Raynaud's and scleroderma. In this trial, we will evaluate the effectiveness and safety of epoprostenol treatment for severe frostbite injury in addition to standard of care.
Interventions
- DRUG Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum
- DRUG Standard of Care + Placebo (Normal Saline)infusion for 8 hours per day up to 5 days maximum
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2026-02 |
| Est. Completion | 2028-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07424378
The ClinicalTrials.gov registry entry for NCT07424378 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum is the first listed.
NCT07424378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07424378 about?
NCT07424378 is a clinical study titled "Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)". Severe frostbite injury can result in significant lifelong disability and amputation. Various medicines, including intravenous vasodilators (prostaglandins/iloprost, pentoxifylline, buflomedil) along with thrombolytics (alteplase), have been described to counter tissue ischemia after rewarming, with...
What is the current status of trial NCT07424378?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2026-02. Estimated completion is 2028-11.
What interventions are being tested in trial NCT07424378?
The interventions under investigation include: Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum (DRUG), Standard of Care + Placebo (Normal Saline)infusion for 8 hours per day up to 5 days maximum (DRUG).
Who is sponsoring clinical trial NCT07424378?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.